Skip to content
IP + Technology Law
Home  »  News & Insights  »  Publications

Lessons From The 1st Biopharma Inter Partes Reviews | Law360

April 16, 2015  | Eli A. Loots, Ph.D.

Recently, the Patent Trial and Appeal Board issued its first set of final written decisions in three inter partes reviews relating to molecules in the large molecule biopharma space (IPR2013-00534, IPR2013- 00535 and IPR2013-00537). Biosimilar companies will no doubt be looking to these decisions as a roadmap for clearing patent landscapes for their own biosimilar products in the coming years. Read more below or download the PDF.

Lessons From The 1st Biopharma Inter Partes Reviews from Knobbe Martens Olson & Bear

Related Links

Practice Areas

Industries

News & Insights

Publications
Jun 2025
In Law360 Column, Sean Murray and Jeremiah Helm Discuss Impact of Federal Circuit Decision on IPR Proceedings
In the latest edition of their Law360 column on noteworthy Federal Circuit rulings, partners Sean Murray and Jeremiah Helm examine the recent decision in Sage Products v. Stewart. The Federal...
Blog - IP Practice
Jun 2025
No Injury, No Appeal: Patent Owners Must Show Actual Injury for Article III Standing
DOLBY LABORATORIES LICENSING CORPORATION v. UNIFIED PATENTS, LLC Before Moore, Clevenger and Chen.  Appeal from the Patent Trial and Appeal Board. Summary: A patent owner lacks Article III standing to...
Blog - IP Practice
Jun 2025
Finding Common Ground? — Federal Circuit Clarifies IPR Estoppel
INGENICO INC. v. IOENGINE, LLC Before Dyk, Prost, and Hughes. Appeal from the United States District Court for the District of Delaware. Summary: IPR estoppel does not preclude reliance on...